Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial. A Phase IV Open-Label Trial Using 150,300, 600 mg/Day Of Pregabalin.

Trial Profile

Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial. A Phase IV Open-Label Trial Using 150,300, 600 mg/Day Of Pregabalin.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 04 Feb 2011

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Partial epilepsies
  • Focus Therapeutic Use
  • Acronyms PREPS
  • Sponsors Pfizer
  • Most Recent Events

    • 27 Oct 2009 Actual patient number (136) added as reported by ClinicalTrials.gov.
    • 09 Jun 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
    • 20 May 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top